245 related articles for article (PubMed ID: 16257382)
41. In vivo preclinical low-field MRI monitoring of tumor growth following a suicide-gene therapy in an orthotopic mice model of human glioblastoma.
Breton E; Goetz C; Kintz J; Accart N; Aubertin G; Grellier B; Erbs P; Rooke R; Constantinesco A; Choquet P
C R Biol; 2010 Mar; 333(3):220-5. PubMed ID: 20338540
[TBL] [Abstract][Full Text] [Related]
42. Report to the NIH Recombinant DNA Advisory Committee on murine replication-competent retrovirus (RCR) assays (February 17, 1993).
Anderson WF; McGarrity GJ; Moen RC
Hum Gene Ther; 1993 Jun; 4(3):311-21. PubMed ID: 8338878
[No Abstract] [Full Text] [Related]
43. Clinical trials with retrovirus mediated gene therapy--what have we learned?
Rainov NG; Ren H
J Neurooncol; 2003 Dec; 65(3):227-36. PubMed ID: 14682373
[TBL] [Abstract][Full Text] [Related]
44. Clinical development of experimental virus-mediated gene therapy for malignant glioma.
Rainov NG; Heidecke V
Anticancer Agents Med Chem; 2011 Oct; 11(8):739-47. PubMed ID: 21707496
[TBL] [Abstract][Full Text] [Related]
45. Targeted Suicide Gene Therapy with Retroviral Replicating Vectors for Experimental Canine Cancers.
Sonoda-Fukuda E; Takeuchi Y; Ogawa N; Noguchi S; Takarada T; Kasahara N; Kubo S
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473904
[TBL] [Abstract][Full Text] [Related]
46. Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario.
Altaner C; Altanerova V; Cihova M; Ondicova K; Rychly B; Baciak L; Mravec B
Int J Cancer; 2014 Mar; 134(6):1458-65. PubMed ID: 24038033
[TBL] [Abstract][Full Text] [Related]
47. Gene therapy for human malignant brain tumors.
Rainov NG; Ren H
Cancer J; 2003; 9(3):180-8. PubMed ID: 12952303
[TBL] [Abstract][Full Text] [Related]
48. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.
Uchibori R; Okada T; Ito T; Urabe M; Mizukami H; Kume A; Ozawa K
J Gene Med; 2009 May; 11(5):373-81. PubMed ID: 19274675
[TBL] [Abstract][Full Text] [Related]
49. [Gene therapy for brain tumors--present conditions and prospects].
Nakahara N; Yoshida J
Gan To Kagaku Ryoho; 2005 Apr; 32(4):458-62. PubMed ID: 15853210
[TBL] [Abstract][Full Text] [Related]
50. Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
Kazlauskas A; Darinskas A; Meškys R; Tamašauskas A; Urbonavičius J
BMC Cancer; 2019 Mar; 19(1):197. PubMed ID: 30832616
[TBL] [Abstract][Full Text] [Related]
51. Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins.
Miletic H; Fischer YH; Neumann H; Hans V; Stenzel W; Giroglou T; Hermann M; Deckert M; Von Laer D
Hum Gene Ther; 2004 Nov; 15(11):1091-100. PubMed ID: 15610609
[TBL] [Abstract][Full Text] [Related]
52. Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide gene-transducing replication-competent foamy virus vectors.
Heinkelein M; Hoffmann U; Lücke M; Imrich H; Müller JG; Meixensberger J; Westphahl M; Kretschmer A; Rethwilm A
Cancer Gene Ther; 2005 Dec; 12(12):947-53. PubMed ID: 15905857
[TBL] [Abstract][Full Text] [Related]
53. Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma.
Miletic H; Fischer YH; Giroglou T; Rueger MA; Winkeler A; Li H; Himmelreich U; Stenzel W; Jacobs AH; von Laer D
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6761-8. PubMed ID: 18006778
[TBL] [Abstract][Full Text] [Related]
54. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.
Miyatake S; Martuza RL; Rabkin SD
Cancer Gene Ther; 1997; 4(4):222-8. PubMed ID: 9253507
[TBL] [Abstract][Full Text] [Related]
55. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses.
Puumalainen AM; Vapalahti M; Agrawal RS; Kossila M; Laukkanen J; Lehtolainen P; Viita H; Paljärvi L; Vanninen R; Ylä-Herttuala S
Hum Gene Ther; 1998 Aug; 9(12):1769-74. PubMed ID: 9721087
[TBL] [Abstract][Full Text] [Related]
56. An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
Kostova Y; Mantwill K; Holm PS; Anton M
Cancer Gene Ther; 2015 Jan; 22(1):30-43. PubMed ID: 25501992
[TBL] [Abstract][Full Text] [Related]
57. An experimental model of retrovirus gene therapy for malignant brain tumors.
Takamiya Y; Short MP; Moolten FL; Fleet C; Mineta T; Breakefield XO; Martuza RL
J Neurosurg; 1993 Jul; 79(1):104-10. PubMed ID: 8391069
[TBL] [Abstract][Full Text] [Related]
58. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus.
Foloppe J; Kintz J; Futin N; Findeli A; Cordier P; Schlesinger Y; Hoffmann C; Tosch C; Balloul JM; Erbs P
Gene Ther; 2008 Oct; 15(20):1361-71. PubMed ID: 18480846
[TBL] [Abstract][Full Text] [Related]
59. Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Cancer Gene Ther; 2007 Mar; 14(3):279-86. PubMed ID: 17218950
[TBL] [Abstract][Full Text] [Related]
60. Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas.
Sasaki M; Wizigmann-Voos S; Risau W; Plate KH
Int J Dev Neurosci; 1999; 17(5-6):579-91. PubMed ID: 10571419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
